Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Intercept Pharmaceuticals revenue
Intercept Pharmaceuticals's revenue is $285.7 million.
What is Intercept Pharmaceuticals's revenue?
- Intercept Pharmaceuticals's revenue growth from 2011 to 2022 is 15,727.67%.
- Intercept Pharmaceuticals has 437 employees, and the revenue per employee ratio is $653,798.
- Intercept Pharmaceuticals's peak quarterly revenue was $88.8M in 2023(q3).
- Intercept Pharmaceuticals peak revenue was $285.7M in 2022.
- Intercept Pharmaceuticals annual revenue for 2021 was 260.8M, 11.45% growth from 2020.
- Intercept Pharmaceuticals annual revenue for 2022 was 285.7M, 9.57% growth from 2021.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Intercept Pharmaceuticals historical revenue
Intercept Pharmaceuticals's peak revenue was $285.7M in 2022. The peak quarterly revenue was $88.8M in 2023(q3).
Intercept Pharmaceuticals's revenue increased from $1.8m in 2011 to $285.7M currently. That's a 15,727.67% change in annual revenue.
Intercept Pharmaceuticals annual revenue
Intercept Pharmaceuticals annual revenue over time
| Fiscal year / year | Intercept Pharmaceuticals revenue |
|---|---|
| 2011 | $1.8M |
| 2012 | $2.4M |
| 2013 | $1.6M |
| 2014 | $1.7M |
| 2015 | $2.8M |
| 2016 | $25.0M |
| 2017 | $131.0M |
| 2018 | $179.8M |
| 2019 | $252.0M |
| 2020 | $234.0M |
| 2021 | $260.8M |
| 2022 | $285.7M |
Rate Intercept Pharmaceuticals' financial transparency
Intercept Pharmaceuticals annual growth
Intercept Pharmaceuticals saw the greatest revenue growth in 2016, when revenue increased by 796.87%.
Intercept Pharmaceuticals had the lowest revenue growth in 2013, when revenue changed by -33.69%.
Intercept Pharmaceuticals annual growth rate over time
| Year | Intercept Pharmaceuticals growth |
|---|---|
| 2012 | 36%↑ |
| 2013 | -34%↓ |
| 2014 | 7%↑ |
| 2015 | 60%↑ |
| 2016 | 797%↑ |
| 2017 | 425%↑ |
| 2018 | 37%↑ |
| 2019 | 40%↑ |
| 2020 | -7%↓ |
| 2021 | 11%↑ |
| 2022 | 10%↑ |
Intercept Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Intercept Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | - | - | $523,191 | $405,405 |
| 2013 | $405,405 | $405,407 | $405,407 | $405,781 |
| 2014 | $405,403 | $445,000 | $445,000 | $446,000 |
| 2015 | $1.4M | $445,000 | $445,000 | $446,000 |
| 2016 | $445,000 | $5.5M | $5.2M | $13.8M |
| 2017 | $21.0M | $30.9M | $41.3M | $37.7M |
| 2018 | $36.0M | $43.6M | $47.0M | $53.3M |
| 2019 | $52.3M | $66.3M | $62.0M | $71.5M |
| 2020 | $72.7M | $77.2M | $79.5M | $4.5M |
| 2021 | $81.7M | $68.2M | $66.6M | $68.6M |
| 2022 | $59.1M | $71.8M | $77.6M | $77.2M |
| 2023 | $68.0M | $83.7M | $88.8M | - |
Intercept Pharmaceuticals jobs nearby
Do you work at Intercept Pharmaceuticals?
Is Intercept Pharmaceuticals transparent about its revenue structure?
Intercept Pharmaceuticals financial information
| CEO | Jerome B. Durso |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 437 |
| Date Founded | 2002 |
| Headquarters | New York, New York |
| Number of Locations | 3 |
| Revenue | $285.7M |
| Net Income | $221,816,000 |
| Gross Proft | $284.7M (2022) |
| PE Ratio | 6.99 |
| Market Capitalization | $1.6B |
| Total Assets | $553,711,000 |
| Ticker | ICPT |
Intercept Pharmaceuticals jobs you might like
Intercept Pharmaceuticals financing
Intercept Pharmaceuticals received early financing of $1.3M on 2005-05-04.
| Series | Round size | Date |
|---|---|---|
| Debt Financing | $1.3M | 05/2005 |
| Series Unknown | $41M | 05/2006 |
| Series A | $25M | 07/2008 |
| Series B | $25M | 01/2010 |
| Series C | $30M | 08/2012 |
| Post Ipo Equity | $61.7M | 06/2013 |
| Post Ipo Equity | $338.4M | 04/2015 |
| Convertible Note | $44.8M | 06/2016 |
Intercept Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Rodman & Renshaw | Debt Financing |
| Balyasny Asset Management | Series Unknown |
| Genextra | Series Unknown |
| Jafco Life Science | Series Unknown |
| Genextra | Series A |
| Genextra | Series B |
| OrbiMed Advisors | Series C |
| Aisling Capital | Series C |
Intercept Pharmaceuticals competitors
Intercept Pharmaceuticals's top competitor, Forest Laboratories, earned an annual revenue of $3.6B.
Intercept Pharmaceuticals's smallest competitor is ImmunoGen with revenue of $108.8M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Medivation | $94,135 | $1.0B | 628 | - |
| Forest Laboratories | $91,901 | $3.6B | 6,200 | - |
| Upsher-Smith Laboratories | $63,937 | $420.0M | 550 | 28 |
| Acorda Therapeutics | $97,279 | $117.6M | 344 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Ligand Pharmaceuticals | $82,001 | $241.5M | 116 | - |
| Ariad Pharmaceuticals | $94,078 | $118.8M | 380 | - |
| ImmunoGen | $64,247 | $108.8M | 75 | - |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 32 |
Intercept Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Intercept Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Intercept Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Intercept Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Intercept Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Intercept Pharmaceuticals. The data presented on this page does not represent the view of Intercept Pharmaceuticals and its employees or that of Zippia.
Intercept Pharmaceuticals may also be known as or be related to INTERCEPT PHARMACEUTICALS INC, INTERCEPT PHARMACEUTICALS INC., Intercept Pharmaceuticals, Intercept Pharmaceuticals Inc and Intercept Pharmaceuticals, Inc.